Navigation Links
Physicians Reconsider Implications of Enhance Trial
Date:2/7/2008

First Impact Report Reveals Shift in Prescribing Patterns As More MDs

Question Clinical Outcomes of Cholesterol-Reducing Drug

NEW YORK, Feb. 7 /PRNewswire/ -- Despite the controversy surrounding the release of the preliminary ENHANCE trial results on January 14, 2008, physicians are less concerned now -- roughly three weeks later -- about the trial results than they were initially, according to a pivotal FirstImpact Report issued today by FirstWord Publishing, publishers of the FirstWord newsletter, the world's leading source of news for the pharmaceutical industry.

The report, FirstImpact: ENHANCE trial results -- physicians evolving reactions, is based on surveys with general practitioners and cardiologists. The ENHANCE clinical trial results showed that Vytorin, a combination of Zetia and Zocor, is no more effective than Zocor in reducing plaque formation in patients with a condition that affects only about 0.2 percent of the population overall.

In the 48 hours after Merck/Schering-Plough released the preliminary results of the ENHANCE clinical trial, 82 percent of surveyed physicians responded that the results would have an impact on their prescribing decisions. A follow-up survey conducted by FirstImpact Reports on January 31 showed that this impact had decreased to 60 percent. Nonetheless, the FirstImpact survey also found that a large group of physicians continued to have negative reactions to the ENHANCE trial.

"There has been considerable speculation about the potential shifts in prescriptions of Vytorin and Zetia as a result of the ENHANCE trial results. But ultimately, it is the attitudes and treatment intentions of practicing physicians that determine how significantly prescriptions for these products will continue to be affected by the fallout of the ENHANCE trial," said Dominique Balas, president of FirstImpact Reports. She continues, "Our research found that while physicians' prescribing intentions have st
'/>"/>

SOURCE FirstImpact Reports
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
4. Physicians Will Benefit from Medical Software Advice Website
5. Oncologists Call For Medicare to Reconsider Anemia Drug Restrictions
6. Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
7. Improved Cornea Surgery Technique Provides Enhanced Transplant Success
8. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
9. Data Demonstrate that Obagi Medical Products Condition & Enhance Skin Care System is an Effective Complement to Facial Rejuvenation Procedures
10. ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion on ENHANCE Trial
11. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014  In anticipation of the upcoming ... being made available for the first time. Industry Overview: ... offers a snapshot of San Diego,s ... Highlighting everything from the latest employment statistics to current venture ... San Diego such a vital part of ...
(Date:8/28/2014)... , Aug. 28, 2014  A candidate Ebola vaccine could be ... and Mali as early as ... vaccines aimed at preventing the disease that has killed more than ... . Human trials of this candidate vaccine, being ... are to be accelerated with funding from an international consortium in ...
(Date:8/28/2014)... , August 28, 2014 According ... Research "Radiofrequency Identification (RFID) Market (Tags, Readers, Middleware, Printers ... Trends and Forecast, 2014 - 2020" the global radiofrequency ... in 2013 and is expected to grow at a ... an estimated value of USD 5.3 billion in 2020. ...
Breaking Medicine Technology:New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2Ebola vaccine trials fast-tracked by international consortium 2Ebola vaccine trials fast-tracked by international consortium 3Ebola vaccine trials fast-tracked by international consortium 4Ebola vaccine trials fast-tracked by international consortium 5Ebola vaccine trials fast-tracked by international consortium 6Ebola vaccine trials fast-tracked by international consortium 7Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5
... Hands Foundation announced today the donation of $75,000 to ... in the United States and Latin America. The money was ... Blue Test, supported by Roche Diabetes Care. The ... World Diabetes Day on Nov. 14. The campaign reinforces the ...
... Generex Biotechnology Corporation (OTCBB: GNBT.OB) ( www.generex.com ) ... ( www.antigenexpress.com ), will present new Phase 2 clinical ... HER-2/neu Peptide Vaccine (AE37) in HER-2 expressing breast cancer ... Cancer Symposium (SABCS) in San Antonio, Texas on December ...
Cached Medicine Technology:Big Blue Test 2011 Provides Life-Saving Insulin and Supplies to More Than 8,000 People in Need 2Big Blue Test 2011 Provides Life-Saving Insulin and Supplies to More Than 8,000 People in Need 3Big Blue Test 2011 Provides Life-Saving Insulin and Supplies to More Than 8,000 People in Need 4Generex Subsidiary Antigen Express to Present AE37 Cancer Vaccine Phase 2 Clinical Data at 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium 2Generex Subsidiary Antigen Express to Present AE37 Cancer Vaccine Phase 2 Clinical Data at 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium 3Generex Subsidiary Antigen Express to Present AE37 Cancer Vaccine Phase 2 Clinical Data at 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium 4Generex Subsidiary Antigen Express to Present AE37 Cancer Vaccine Phase 2 Clinical Data at 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium 5
(Date:8/29/2014)... (PRWEB) August 29, 2014 When subjected ... has been found to be one of the most ... , DISC, MBTI, the Hartman Personality Profile, and the ... of testing personality. Each of these testing tools uses ... personality type. Once personality type has been identified, the ...
(Date:8/29/2014)... How can you make your ... top notch services. Dr. Michael Fiorillo knows this ... with a double board certified surgeon and vein ... websites! , Dr. Fiorillo’s services include a wide ... Some of these are breast augmentation, breast lift, ...
(Date:8/29/2014)... 29, 2014 According to Macmillan Cancer ... (NCIN) conference held in Birmingham, England last June, “More ... their disease recur”. This only goes to show how ... are struggling to fight its grueling series of treatments. ... woman’s journey through breast cancer is featured in the ...
(Date:8/29/2014)... Raton, Florida (PRWEB) August 29, 2014 ... which surgeons, like Dr. Scott Katzman of Orthopedic ... instruments to view and perform repairs. Problems with ... the vertebrae cause a number of treatment needs that ... type spine surgery involves an advantageously small incision and ...
(Date:8/29/2014)... Today, Progene reaches another milestone as the only ... healthcare network , but also with enrolled providers nationwide ... a few weeks ago. Today, we’re now recommended by ... , The network adds an unprecedented level of service ... before and after they make a purchase -- with the ...
Breaking Medicine News(10 mins):Health News:DISC Personality Tests Demonstrate High Rates of “Test-Retest Reliability” 2Health News:DISC Personality Tests Demonstrate High Rates of “Test-Retest Reliability” 3Health News:Michael Fiorillo’s Advanced Plastic Surgery Center Expansion – New Vein Specialist and Websites Launch 2Health News:Michael Fiorillo’s Advanced Plastic Surgery Center Expansion – New Vein Specialist and Websites Launch 3Health News:Lisa Grimaldi Shares Her Fashionable Journey through Breast Cancer 2Health News:Advancements in Spine Surgery Offered by this Modern Florida Surgery Group are Cutting Out Historically Demanding Recovery Times 2Health News:Progene Is Doctor Recommended Nationwide 2Health News:Progene Is Doctor Recommended Nationwide 3
... injured after a strong earthquake with a magnitude of ... Sunday. ,The quake shook the old downtown area ... at 5:34 a.m., with the epicentre at 23 degrees north ... ,The quake also forced the evacuation of 120,000 ...
... patients with culture-positive tuberculosis (TB), relapse rates were ... patients compared to HIV-uninfected patients following a rifamycin-based ... HIV-infected patients who received intermittent or standard 6-month ... longer treatment. ,The results appear in ...
... has been regularly urging the developing world to look for ... their public health services. But many nations in the African ... challenge before them. ,Like elsewhere in the third ... capital city of Lusaka hundreds of persons walking aimlessly along ...
... to assess the reproductive health needs of women displaced ... developed by the Centers for Disease Control and ... world's refugees and internally displaced people are women and ... Conflict- Affected Women, is the response of the CDC's ...
... plan of the US should complement rather than substitute the ... (UNFCCC), China's top economic planner Ma Kai said Monday. ... differentiated responsibilities in the UNFCCC and some details in the ... Ma said at a press conference. ,He said ...
... DuRant, Ph.D., and his colleagues' at Brenner Children's Hospital, ... have carried out a research study on the safety ... in the June issue of Pediatrics. ,'Over ... their firearms safely in their residence,' DuRant said. 'This ...
Cached Medicine News:Health News:Treatment Outcomes of Patients With HIV and Tuberculosis 2Health News:Zambia Trying Hard to Tackle Crisis in Mental Health Care 2Health News:Toolkit to Assess Reproductive Health Needs of Displaced Women 2Health News:Storage of Firearms Unsafe in Most Families 2
Cholesterol FS. For determination of cholesterol in serum or plasma. Available with Calibrator: Trucal U and Controls: Trulab N, Trulab P Trulab L....
For the quantitative determination of total cholesterol in serum....
Intended for the quantitative determination of total cholesterol in serum. Reaction: Endpoint. Reaction complete within five minutes. Wavelength: 500 nm. Linearity: 700 mg/dL (18.1 mmol/L). Single st...
... determination of Cholesterol in serum. ... 520 nm. Linearity: 500 mg/dl. ... simple 1:25 dilution and is ... 2-8 C. Liquid kit stability: ...
Medicine Products: